Visium Asset Management’s Clovis Oncology, Inc. CLVS Stock Holding History

Visium Asset Management’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-500,000	Closed	-$9.6M	–	525
2016 Q1	$9.6M	Sell	500,000 -36,967	-7%	-$782K	0.16%	159
2015 Q4	$18.8M	Sell	536,967 -244,811	-31%	-$15.8M	0.28%	75
2015 Q3	$71.9M	Buy	781,778 +30,955	+4%	+$2.68M	0.98%	17
2015 Q2	$66M	Buy	750,823 +93,831	+14%	+$8.03M	0.94%	14
2015 Q1	$48.8M	Sell	656,992 -270,847	-29%	-$19.1M	0.72%	17
2014 Q4	$52M	Buy	927,839 +137,504	+17%	+$7.23M	0.73%	25
2014 Q3	$35.8M	Buy	790,335 +402	+0.1%	+$16.8K	0.53%	30
2014 Q2	$32.7M	Sell	789,933 -369,690	-32%	-$19M	0.51%	32
2014 Q1	$80.3M	Buy	1,159,623 +598,439	+107%	+$43.9M	1.3%	11
2013 Q4	$33.8M	Buy	561,184 +223,125	+66%	+$12.1M	0.66%	23
2013 Q3	$20.5M	Buy	338,059 +127,089	+60%	+$9.01M	0.47%	49
2013 Q2	$14.1M	Buy	+210,970	New	+$9.49M	0.33%	62

Other funds holding CLVS

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Visium Asset Management's CLVS Position: Q2 2016 in Review

Visium Asset Management sold out of Clovis Oncology, Inc. (CLVS) in Q2 2016, closing a stake of 500,000 shares — an estimated $9.6M sold.

Visium Asset Management first reported a position in CLVS in Q2 2013 and held it in 12 quarters. The position peaked at $80.3M in Q1 2014. 122 funds tracked by Wall St. Rank hold CLVS as of Q2 2016.

Visium Asset Management reported no remaining Clovis Oncology, Inc. position as of Q2 2016 after selling out during the quarter.
Visium Asset Management sold 500,000 Clovis Oncology, Inc. shares in Q2 2016, an estimated $9.6M.
Visium Asset Management first reported a position in Clovis Oncology, Inc. in Q2 2013 and held it in 12 quarters.
Visium Asset Management's Clovis Oncology, Inc. position peaked at $80.3M in Q1 2014.
122 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2016.

Based on Visium Asset Management's 13F filing for Q2 2016, filed 12 Aug 2016.